SEK 101.1
(2.17%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 26.35 Million SEK | 436.45% |
2022 | 4.91 Million SEK | -49.93% |
2021 | 9.81 Million SEK | -52.51% |
2020 | 20.66 Million SEK | 81.25% |
2019 | 11.4 Million SEK | 0.0% |
2018 | - SEK | 0.0% |
2017 | - SEK | 0.0% |
2016 | - SEK | 0.0% |
2015 | - SEK | 0.0% |
2014 | - SEK | 0.0% |
2013 | - SEK | 0.0% |
2012 | - SEK | 0.0% |
2011 | - SEK | 0.0% |
2010 | - SEK | 0.0% |
2009 | - SEK | 0.0% |
2008 | - SEK | 0.0% |
2007 | - SEK | 0.0% |
2006 | - SEK | 0.0% |
2005 | - SEK | 0.0% |
2004 | - SEK | 0.0% |
2003 | - SEK | -100.0% |
2002 | 7.85 Million SEK | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q3 | - SEK | 0.0% |
2024 Q1 | - SEK | 0.0% |
2024 Q2 | - SEK | 0.0% |
2023 FY | 26.35 Million SEK | 436.45% |
2023 Q4 | 26.35 Million SEK | 0.0% |
2023 Q1 | - SEK | -100.0% |
2023 Q3 | - SEK | 0.0% |
2023 Q2 | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 Q4 | 4.91 Million SEK | 0.0% |
2022 FY | 4.91 Million SEK | -49.93% |
2022 Q1 | - SEK | -100.0% |
2022 Q2 | - SEK | 0.0% |
2021 Q1 | 16.63 Million SEK | -19.51% |
2021 FY | 9.81 Million SEK | -52.51% |
2021 Q2 | 16.03 Million SEK | -3.61% |
2021 Q4 | 9.81 Million SEK | -27.85% |
2021 Q3 | 13.6 Million SEK | -15.16% |
2020 Q3 | - SEK | 0.0% |
2020 Q2 | - SEK | 0.0% |
2020 Q4 | 20.66 Million SEK | 0.0% |
2020 Q1 | - SEK | -100.0% |
2020 FY | 20.66 Million SEK | 81.25% |
2019 Q1 | 16.25 Million SEK | 0.0% |
2019 FY | 11.4 Million SEK | 0.0% |
2019 Q4 | 11.4 Million SEK | -6.47% |
2019 Q3 | 12.18 Million SEK | -12.37% |
2019 Q2 | 13.9 Million SEK | -14.44% |
2018 Q4 | - SEK | 0.0% |
2018 Q1 | - SEK | 0.0% |
2018 Q2 | - SEK | 0.0% |
2018 Q3 | - SEK | 0.0% |
2018 FY | - SEK | 0.0% |
2017 Q2 | - SEK | 0.0% |
2017 FY | - SEK | 0.0% |
2017 Q4 | - SEK | 0.0% |
2017 Q3 | - SEK | 0.0% |
2017 Q1 | - SEK | 0.0% |
2016 Q4 | - SEK | 0.0% |
2016 FY | - SEK | 0.0% |
2016 Q3 | - SEK | 0.0% |
2016 Q2 | - SEK | 0.0% |
2016 Q1 | - SEK | 0.0% |
2015 Q4 | - SEK | 0.0% |
2015 Q2 | - SEK | 0.0% |
2015 Q3 | - SEK | 0.0% |
2015 FY | - SEK | 0.0% |
2015 Q1 | - SEK | 0.0% |
2014 FY | - SEK | 0.0% |
2014 Q2 | - SEK | 0.0% |
2014 Q3 | - SEK | 0.0% |
2014 Q4 | - SEK | 0.0% |
2014 Q1 | - SEK | 0.0% |
2013 FY | - SEK | 0.0% |
2013 Q1 | - SEK | 0.0% |
2013 Q4 | - SEK | 0.0% |
2013 Q3 | - SEK | 0.0% |
2013 Q2 | - SEK | 0.0% |
2012 Q1 | - SEK | 0.0% |
2012 Q2 | - SEK | 0.0% |
2012 Q4 | - SEK | 0.0% |
2012 Q3 | - SEK | 0.0% |
2012 FY | - SEK | 0.0% |
2011 FY | - SEK | 0.0% |
2011 Q2 | - SEK | 0.0% |
2011 Q1 | - SEK | 0.0% |
2011 Q4 | - SEK | 0.0% |
2011 Q3 | - SEK | 0.0% |
2010 Q2 | - SEK | 0.0% |
2010 Q3 | - SEK | 0.0% |
2010 FY | - SEK | 0.0% |
2010 Q4 | - SEK | 0.0% |
2010 Q1 | - SEK | 0.0% |
2009 FY | - SEK | 0.0% |
2009 Q4 | - SEK | 0.0% |
2009 Q2 | - SEK | 0.0% |
2008 FY | - SEK | 0.0% |
2007 FY | - SEK | 0.0% |
2006 FY | - SEK | 0.0% |
2005 FY | - SEK | 0.0% |
2004 FY | - SEK | 0.0% |
2003 FY | - SEK | -100.0% |
2002 FY | 7.85 Million SEK | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
AcuCort AB | - SEK | -Infinity% |
AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
Enzymatica AB (publ) | 24.88 Million SEK | -5.915% |
Enorama Pharma AB (publ) | 303 Thousand SEK | -8598.35% |
Gabather AB (publ) | - SEK | -Infinity% |
Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
Moberg Pharma AB (publ) | 3.46 Million SEK | -660.196% |
Nanexa AB (publ) | 2.08 Million SEK | -1162.865% |
Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
ODI Pharma AB | - SEK | -Infinity% |
Orexo AB (publ) | 448.4 Million SEK | 94.122% |
Probi AB (publ) | 38.21 Million SEK | 31.027% |
Swedencare AB (publ) | 1.44 Billion SEK | 98.171% |
Swedish Orphan Biovitrum AB (publ) | 11.35 Billion SEK | 99.768% |
Toleranzia AB | 850 Thousand SEK | -3000.706% |
Vivesto AB | 5.18 Million SEK | -408.705% |